3221 Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice

th line. Most common adverse events (≥ 15%) are thrombocytopenia (39.5%), anemia (15.8%) and general physical health deterioration (18.4%). Severe adverse events (drug related) are general, metabolic, psychiatric, skin, renal, gastrointestinal and blood system disorders (in 1 pt each) and infections (in 2 pts). Preliminary efficacy analyses are available for 27 assessable pts and show an objective response in 8 pts (1CR and 7 PR, 29.6%), a clinical benefit (CR, PR, MR and SD) in 16 pts (59.3%) and PD in 11 pts (40.7%). Median PFS is 4.2 months. Conclusions: The registry was started to evaluate the safety and efficacy of TEMS in pts with rez/refr MCL in the routine clinical practice. In this here included patient collective with 44.4% high-risk pts, TEMS shows a predictable, manageable tolerability profile and efficacy remains comparable with phase III data. Disclosure: G. Krekeler: Employee of Pfizer GmbH, Germany; M.H. Dreyling: membership on an advisory board; G. Hess: membership on an advisory board, cooperate-sponsored research; D. Kalanovic: Employee of Pfizer GmbH.